All In Biotech

NDA 210498 · Array Biopharma INC

Mektovi

Binimetinib · Oral

NovelOrphan

Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jun 27, 2018

Approved uses

5

Original approval plus efficacy supplements

Registered trials

133

8 Phase 3, 18 recruiting

FAERS reports

7,953

5,553 serious, 1,246 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 20, 2025.

MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.2 , 2.1 ) 1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . 1.2 BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) MEKTOVI is indicated, in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. [see Dosage and Administration (2.1) ] .

Mechanism: Binimetinib is a reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. In vitro, binimetinib inhibited extracellular signal-related kinase (ERK) phosphorylation in cell-free assays as well as viability and MEK-dependent phosphorylation of BRAF-mutant human melanoma cell lines. Binimetinib also inhibited in vivo ERK phosphorylation and tumor growth in BRAF-mutant murine xenograft models. Binimetinib and encorafenib target two different kinases in...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MEKTOVI · BINIMETINIB 15MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Binimetinib" as an intervention, any sponsor and status, largest first.

All 133 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use976
  • death836
  • nausea731
  • fatigue611
  • diarrhoea579
  • pyrexia556
  • product use in unapproved indication524
  • vomiting420
  • rash407
  • neoplasm progression395
  • serous retinal detachment359
  • malaise233

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20162
201710
2018258
20191,355
20201,273
2021914
2022923
2023969
2024849
2025844
2026556

Recalls

1 FDA enforcement reports for this application.

  • Mar 8, 2023 · Class III · Ongoing

    Labeling: Incorrect or Missing Lot and/or Exp Date: The carton and bottle labels state an expiry date of March 2026; the correct expiration date is February 2025.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mektovi (Binimetinib)

2024 spending

$96.2M

Beneficiaries

1,364

7,307 claims

Per beneficiary

$70,514

$84.70 per unit

View as table
YearSpending
2020$48,497,193
2021$64,201,143
2022$73,003,223
2023$56,654,059
2024$96,181,636

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 103 on PubMed

Sponsor: Array Biopharma INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.